JP6640725B2 - ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す - Google Patents

ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す Download PDF

Info

Publication number
JP6640725B2
JP6640725B2 JP2016548687A JP2016548687A JP6640725B2 JP 6640725 B2 JP6640725 B2 JP 6640725B2 JP 2016548687 A JP2016548687 A JP 2016548687A JP 2016548687 A JP2016548687 A JP 2016548687A JP 6640725 B2 JP6640725 B2 JP 6640725B2
Authority
JP
Japan
Prior art keywords
analog
spadin
seq
propeptide
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016548687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505772A5 (OSRAM
JP2017505772A (ja
Inventor
ガウドリアウルト ゲオルゲス
ガウドリアウルト ゲオルゲス
ヘウルテアウク カトリーヌ
ヘウルテアウク カトリーヌ
マゼラ ジャン
マゼラ ジャン
ボルソト マルク
ボルソト マルク
モハ オウ マティ ハミド
モハ オウ マティ ハミド
ベイシエレ ジュリエ
ベイシエレ ジュリエ
Original Assignee
セントレ ナショナル デ ラ レチャーチェ シャーティフィック
セントレ ナショナル デ ラ レチャーチェ シャーティフィック
ウニヴェルシテ デ ニシエ ソプフィア アントイポリス
ウニヴェルシテ デ ニシエ ソプフィア アントイポリス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントレ ナショナル デ ラ レチャーチェ シャーティフィック, セントレ ナショナル デ ラ レチャーチェ シャーティフィック, ウニヴェルシテ デ ニシエ ソプフィア アントイポリス, ウニヴェルシテ デ ニシエ ソプフィア アントイポリス filed Critical セントレ ナショナル デ ラ レチャーチェ シャーティフィック
Publication of JP2017505772A publication Critical patent/JP2017505772A/ja
Publication of JP2017505772A5 publication Critical patent/JP2017505772A5/ja
Application granted granted Critical
Publication of JP6640725B2 publication Critical patent/JP6640725B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016548687A 2014-01-27 2015-01-27 ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す Expired - Fee Related JP6640725B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931954P 2014-01-27 2014-01-27
US61/931,954 2014-01-27
PCT/IB2015/000338 WO2015110915A2 (en) 2014-01-27 2015-01-27 Retro-inverso analogs of spadin display increased antidepressant effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019174139A Division JP2020023508A (ja) 2014-01-27 2019-09-25 ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す

Publications (3)

Publication Number Publication Date
JP2017505772A JP2017505772A (ja) 2017-02-23
JP2017505772A5 JP2017505772A5 (OSRAM) 2018-03-08
JP6640725B2 true JP6640725B2 (ja) 2020-02-05

Family

ID=53264690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016548687A Expired - Fee Related JP6640725B2 (ja) 2014-01-27 2015-01-27 ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
JP2019174139A Pending JP2020023508A (ja) 2014-01-27 2019-09-25 ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019174139A Pending JP2020023508A (ja) 2014-01-27 2019-09-25 ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す

Country Status (5)

Country Link
US (1) US10251937B2 (OSRAM)
EP (1) EP3099313B1 (OSRAM)
JP (2) JP6640725B2 (OSRAM)
CA (1) CA2938019A1 (OSRAM)
WO (1) WO2015110915A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3377041T3 (fi) 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
FR3057266B1 (fr) * 2016-10-11 2021-05-21 Centre Nat Rech Scient Peptides derives du propeptide ntsr3 et leur utilisation dans le traitement de la depression
KR102250582B1 (ko) * 2018-05-11 2021-05-12 고려대학교 산학협력단 별아교세포 특이적 수동전도도 억제약물의 스크리닝 시스템 및 이의 활용
FR3099932B1 (fr) 2019-08-13 2022-11-25 Univ Limoges Peptides dérivés de la sortiline
US20240294603A1 (en) * 2023-03-02 2024-09-05 Transdermal Biotechnology, Inc. Systems and methods for delivery of spadin for treatment of depression or other indications
US11980651B1 (en) * 2023-06-21 2024-05-14 Transdermal Biotechnology, Inc. Systems and methods for treatment of hearing using dihexa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8066997B2 (en) * 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
KR101614558B1 (ko) * 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
SG10201508568VA (en) 2010-12-29 2015-11-27 Medincell Biodegradable drug delivery compositions
US20120322060A1 (en) * 2011-04-13 2012-12-20 Centre National De Le Recherche Scientifique - Cnrs - Diagnosis and monitoring treatment of psychiatric diseases with spadin and related methods
BR112014031773B1 (pt) 2012-06-27 2020-10-13 Medincell composição de liberação de drogas biodegradáveis hidrofóbicas

Also Published As

Publication number Publication date
JP2020023508A (ja) 2020-02-13
EP3099313B1 (en) 2021-04-21
CA2938019A1 (en) 2015-07-30
US10251937B2 (en) 2019-04-09
WO2015110915A2 (en) 2015-07-30
WO2015110915A3 (en) 2015-11-26
EP3099313A2 (en) 2016-12-07
US20170072013A1 (en) 2017-03-16
JP2017505772A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
JP6640725B2 (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
US11723894B2 (en) Combination product for the treatment of neurological and/or psychiatric disorders
Ma et al. A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway
JP2010528016A (ja) 細胞を刺激するための方法および組成物
KR102508651B1 (ko) 신경계 및 신경변성 상태의 요법으로서 장기간 작용하는 glf-1r 작용제
NZ587312A (en) Combination of alpha 7 nicotinic agonists and antipsychotics
ES2925550T3 (es) Trastornos neurodegenerativos
US20250205302A1 (en) Compositions and methods for the treatment of neurodamage
US20250177490A1 (en) Compositions and methods for promoting islet viability and enhancing insulin secretion
PT2212349E (pt) Análogos sintéticos de péptidos de regeneração neural
EP3468602B1 (en) Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
ES2935705T3 (es) Un ligando del receptor GABA A
JP7445978B2 (ja) 抗エリスロポエチン受容体ペプチド
JP7069126B2 (ja) 化学療法誘発性末梢性ニューロパシーおよび難聴を処置または予防するためのｂｃｌ－ｗポリペプチドおよび模倣物
EP3341739A1 (en) Mutant peptides and methods of treating subjects using the same
US20230174582A1 (en) Vipr2 antagonist peptide
CN107428811B (zh) 用于治疗和/或诊断阿尔茨海默氏痴呆症的特异性结合A-β-物类的肽
JP2001507924A (ja) コナントキン類
JP5671465B2 (ja) 気分障害および不安障害の治療
WO2020172686A9 (en) Amyloid peptide variants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190925

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191226

R150 Certificate of patent or registration of utility model

Ref document number: 6640725

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees